{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:54:19Z","timestamp":1765486459962,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Drug-drug interaction (DDI) potentials of lusutrombopag, a thrombopoietin receptor agonist, on the activity of cytochrome P450 (CYP) 3A and of cyclosporine, which inhibits P-glycoprotein and breast cancer resistance protein, on lusutrombopag pharmacokinetics were assessed via clinical studies and physiologically based pharmacokinetic (PBPK) modeling.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The effect of lusutrombopag on midazolam (a CYP3A probe substrate) pharmacokinetics was assessed in 15 healthy subjects receiving a single midazolam 5-mg dose with or without coadministration of lusutrombopag 0.75\u00a0mg for 6\u00a0days (first dose: 1.5-mg dose). The effect of cyclosporine on lusutrombopag pharmacokinetics was assessed in 16 healthy subjects receiving a single lusutrombopag 3-mg dose with or without a single cyclosporine 400- to 600-mg dose. PBPK modeling was employed to extrapolate the effect of lusutrombopag at the clinical dose (3\u00a0mg once daily) on midazolam pharmacokinetics.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the clinical study, mean ratios (90% confidence intervals [CIs]) of with\/without lusutrombopag for maximum plasma concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) and area under the plasma concentration-time curve (AUC) of midazolam were 1.01 (0.908\u20131.13) and 1.04 (0.967\u20131.11), respectively, indicating no effect of lusutrombopag on midazolam pharmacokinetics. PBPK modeling suggested no effect of lusutrombopag at the clinical dose on midazolam pharmacokinetics. Mean ratios (90% CIs) of with\/without cyclosporine for lusutrombopag <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and AUC were 1.18 (1.11\u20131.24) and 1.19 (1.13\u20131.25), respectively, indicating a slight increase in lusutrombopag exposure.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In consideration with in vitro data, the in vivo and in silico results suggested no clinically significant DDI potential of lusutrombopag with other medical products via metabolic enzymes and transporters.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00228-020-02960-7","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T10:04:08Z","timestamp":1594721048000},"page":"1659-1665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-716X","authenticated-orcid":false,"given":"Takayuki","family":"Katsube","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Wajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"issue":"6","key":"2960_CR1","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","volume":"48","author":"N Afdhal","year":"2008","unstructured":"Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R (2008) Thrombocytopenia associated with chronic liver disease. J Hepatol 48(6):1000\u20131007. https:\/\/doi.org\/10.1016\/j.jhep.2008.03.009","journal-title":"J Hepatol"},{"issue":"1","key":"2960_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40265-015-0525-4","volume":"76","author":"ES Kim","year":"2016","unstructured":"Kim ES (2016) Lusutrombopag: first global approval. Drugs 76(1):155\u2013158. https:\/\/doi.org\/10.1007\/s40265-015-0525-4","journal-title":"Drugs"},{"key":"2960_CR3","unstructured":"Shionogi Inc. (2018) MULPLETA\u00ae (lusutrombopag tablets) for oral use [prescribing information]. Shionogi Inc., Florham Park"},{"key":"2960_CR4","unstructured":"European Medicines Agency (2019) Mulpleo (lusutrombopag) [summary of product characteristics]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mulpleo-previously-lusutrombopag-shionogi-epar-product-information_en.pdf. Accessed 2 Oct 2019"},{"key":"2960_CR5","unstructured":"FDA\u2019s web site on drug development and drug interactions. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers"},{"issue":"3","key":"2960_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215\u2013236. https:\/\/doi.org\/10.1038\/nrd3028","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2960_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0091270006296523","volume":"47","author":"R Krishna","year":"2007","unstructured":"Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, Wang A, Zeng W, Chen L, Wagner J, Herman G (2007) Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 47(2):165\u2013174","journal-title":"J Clin Pharmacol"},{"key":"2960_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/bdd.715","volume":"31","author":"JM Kovarik","year":"2010","unstructured":"Kovarik JM, Stitah S, Slade A, Vitaliti A, Straube F, Grenet O, Winter S, Sfikas N, Seiberling M (2010) Sotrastaurin and cyclosporine drug interaction study in healthy subjects. Biopharm Drug Dispos 31:331\u2013339. https:\/\/doi.org\/10.1002\/bdd.715","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"2960_CR9","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s40262-016-0411-6","volume":"55","author":"T Katsube","year":"2016","unstructured":"Katsube T, Ishibashi T, Kano T, Wajima T (2016) Population pharmacokinetic and pharmacodynamic modeling of lusutrombopag, a newly developed oral thrombopoietin receptor agonist, in healthy subjects. Clin Pharmacokinet 55(11):1423\u20131433. https:\/\/doi.org\/10.1007\/s40262-016-0411-6","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2960_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.clinthera.2019.06.004","volume":"41","author":"T Katsube","year":"2019","unstructured":"Katsube T, Wajima T, Fukuhara T, Kano T (2019) Effects of food and calcium carbonate on the pharmacokinetics of lusutrombopag, a novel thrombopoietin receptor agonist. Clin Ther 41(9):1747\u20131754. https:\/\/doi.org\/10.1016\/j.clinthera.2019.06.004","journal-title":"Clin Ther"},{"key":"2960_CR11","unstructured":"Shionogi BV (2019) EPAR product information. Amsterdam: Lusutrombopag Shionogi. https:\/\/www.ema.europa.eu\/documents\/product-information\/lusutrombopag-shionogi-eparproduct-information_en.pdf"},{"key":"2960_CR12","unstructured":"U.S. Food and Drug Administration (2020) Clinical drug interaction studies \u2014cytochrome P450 enzyme- and transporter-mediated drug interactions. Guidance for Industry"},{"key":"2960_CR13","unstructured":"U.S. Food and Drug Administration (2020) In vitro drug interaction studies \u2014cytochrome P450 enzyme- and transporter-mediated drug interactions. Guidance for Industry"},{"issue":"11","key":"2960_CR14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s40262-019-00770-4","volume":"58","author":"T Katsube","year":"2019","unstructured":"Katsube T, Shimizu R, Fukuhara T, Kano T, Wajima T (2019) Pharmacokinetic\/ pharmacodynamic modelling and simulation of lusutrombopag, a novel thrombopoietin receptor agonist, for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures. Clin Pharmacokinet 58(11):1469\u20131482. https:\/\/doi.org\/10.1007\/s40262-019-00770-4","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2960_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1067\/mcp.2001.115447","volume":"69","author":"T Tateishi","year":"2001","unstructured":"Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, Kobayashi S, Thummel KE, Wilkinson GR (2001) CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 69(5):333\u2013339","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"2960_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/004982599238227","volume":"29","author":"DFV Lewis","year":"1999","unstructured":"Lewis DFV, Lake BG (1999) Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102. Xenobiotica 29(8):763\u2013781","journal-title":"Xenobiotica"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02960-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02960-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02960-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:22:06Z","timestamp":1626218526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02960-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2960"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02960-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"29 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T. Katsube, Y. Inoue, T. Fukuhara, T Kano, T. Wajima: Employees, Shionogi & Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Two clinical were conducted under the principles of the declaration of Helsinki. The implementation of these studies was approved by the institutional review boards in IntegReview (Austin, TX) for Study 1 and CPC Clinical Trial Hospital (Kagoshima, Japan) for Study 2.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Subjects reviewed any study instructions and informed consent form, and were given the time and opportunity to have any questions concerning the conduct of the study answered to their satisfaction.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}